One major challenge is the heterogeneity of cancer cells. Different cell lines or even cells within the same tumor can respond differently to the same drug. Additionally, factors like the presence of the tumor microenvironment, genetic mutations, and drug efflux mechanisms can affect IC50 measurements. Therefore, it is often necessary to use multiple cell lines and complementary assays to get a comprehensive understanding of a drug's efficacy.
